This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. ETHZ, SBTX, AVTE, NLTX, BIOA, VIRI, WHWK, LITS, SPRB, and ELYMShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Lite Strategy (LITS), Spruce Biosciences (SPRB), and Eliem Therapeutics (ELYM). Ritter Pharmaceuticals vs. Its Competitors Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Virios Therapeutics Whitehawk Therapeutics Lite Strategy Spruce Biosciences Eliem Therapeutics Flag Ship Acquisition (NASDAQ:ETHZ) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Which has preferable earnings and valuation, ETHZ or RTTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlag Ship AcquisitionN/AN/A-$6.17M-$15.07-0.11Ritter PharmaceuticalsN/AN/A-$10.13MN/AN/A Do analysts prefer ETHZ or RTTR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ETHZ or RTTR? In the previous week, Flag Ship Acquisition had 4 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 4 mentions for Flag Ship Acquisition and 0 mentions for Ritter Pharmaceuticals. Flag Ship Acquisition's average media sentiment score of 0.27 beat Ritter Pharmaceuticals' score of 0.00 indicating that Flag Ship Acquisition is being referred to more favorably in the media. Company Overall Sentiment Flag Ship Acquisition Neutral Ritter Pharmaceuticals Neutral Which has more risk and volatility, ETHZ or RTTR? Flag Ship Acquisition has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, suggesting that its share price is 143% less volatile than the S&P 500. Is ETHZ or RTTR more profitable? Ritter Pharmaceuticals' return on equity of 0.00% beat Flag Ship Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Flag Ship AcquisitionN/A -141.25% -80.77% Ritter Pharmaceuticals N/A N/A -162.05% Do insiders and institutionals hold more shares of ETHZ or RTTR? 4.1% of Flag Ship Acquisition shares are owned by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 5.4% of Flag Ship Acquisition shares are owned by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryFlag Ship Acquisition beats Ritter Pharmaceuticals on 8 of the 10 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.77M$1.02B$6.13B$10.46BDividend YieldN/A4.84%5.73%4.78%P/E Ratio-6.191.3185.1527.20Price / SalesN/A31.30574.61178.68Price / CashN/A17.6437.3961.86Price / Book39.607.9212.396.65Net Income-$10.13M-$7.71M$3.32B$276.79M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.96+3.9%N/A+2,162.5%$182.77MN/A-6.197ETHZFlag Ship AcquisitionN/A$2.33-8.6%N/AN/A$419.30MN/A-0.157News CoverageStock SplitSBTXSilverback TherapeuticsN/A$10.27-0.4%N/A-30.0%$370.32MN/A-4.2483High Trading VolumeAVTEAerovate TherapeuticsN/A$9.14+3.2%N/A-87.6%$264.92MN/A-3.0620News CoverageHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$23.09+3.4%N/A-33.6%$217MN/A-7.4290High Trading VolumeBIOABioAge Labs0.1457 of 5 stars$5.60-0.5%N/AN/A$201.84MN/A0.00N/APositive NewsVIRIVirios TherapeuticsN/A$6.69+4.4%$5.00-25.3%+70.5%$128.84MN/A-24.785News CoverageGap DownWHWKWhitehawk Therapeutics1.4069 of 5 stars$2.22+3.3%N/AN/A$101.33M$25.98M-37.0021News CoveragePositive NewsGap UpLITSLite StrategyN/A$2.45-5.8%N/AN/A$92.70M$65.30M0.00100SPRBSpruce Biosciences0.7441 of 5 stars$182.60+40.0%$131.25-28.1%+353.9%$73.24M$4.91M-2.1220News CoverageAnalyst ForecastELYMEliem TherapeuticsN/A$1.81-8.6%N/A-65.4%$53.85MN/A-3.429 Related Companies and Tools Related Companies Flag Ship Acquisition Competitors Silverback Therapeutics Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors BioAge Labs Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors Lite Strategy Competitors Spruce Biosciences Competitors Eliem Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
